Novel Bruton's tyrosine kinase inhibitors currently in development

OncoTargets and Therapy

Volumn 6, Issue , 2013, Pages 161-176

  D'Cruz, Osmond J ^a   Uckun, Fatih M ^a,b  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Btk; Kinase inhibitors; Leukemia; Lymphoma; Personalized therapy; Tyrosine kinase

Indexed keywords

2 CYANO N (2,5 DIBROMOPHENYL) 3 HYDROXYCROTONAMIDE; AVL 101; AVL 291; AVL 292; B LYMPHOCYTE RECEPTOR; BENDAMUSTINE; BORTEZOMIB; BRUTON TYROSINE KINASE; BRUTON TYROSINE KINASE INHIBITOR; CYCLOPHOSPHAMIDE; DASATINIB; FLUDARABINE; GDC 0834; IBRUTINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OFATUMUMAB; ONO WG 307; PLACEBO; RITUXIMAB; SMALL INTERFERING RNA; STAT5 PROTEIN; TEMSIROLIMUS; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTHRITIS; ARTICLE; B CELL LEUKEMIA; B CELL LYMPHOMA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CHEMOSENSITIVITY; CHEMOTHERAPY INDUCED ANEMIA; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CYTOPENIA; DIARRHEA; DOSE RESPONSE; DRUG BINDING SITE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG STRUCTURE; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FOLLICULAR LYMPHOMA; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATOSPLENOMEGALY; HUMAN; HYPONATREMIA; INFECTION; LARGE CELL LYMPHOMA; LEUKEMIA REMISSION; LYMPHOCYTOMA; LYMPHOCYTOSIS; LYMPHOMA; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MOLECULARLY TARGETED THERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PNEUMONIA; PRE B LYMPHOCYTE; PROLYMPHOCYTIC LEUKEMIA; PROMYELOCYTIC LEUKEMIA; RNA INTERFERENCE; SINGLE DRUG DOSE; SOLID TUMOR; T CELL LEUKEMIA; T CELL LYMPHOMA; THROMBOCYTOPENIA; TUMOR MICROENVIRONMENT; URINARY TRACT INFECTION; WALDENSTROEM MACROGLOBULINEMIA; WHOLE BODY RADIATION;

EID: 84875032090     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S33732     Document Type: Article

References (161)

1. Kurosaki T, Tsukada S. BLNK: connecting Syk and Btk to calcium signals. Immunity. 2000;12:1-5.
2. Schwartzberg PL, Finkelstein LD, Readinger JA. TEC-family kinases: regulators of T-helper-cell differentiation. Nat Rev Immunol. 2005;5:284-295.
3. Mahajan S, Vassilev A, Sun N, Ozer Z, Mao C, Uckun FM. Transcription factor STAT5A is a substrate of Bruton's tyrosine kinase in B cells. J Biol Chem. 2001;276:31216-31228.
4. Glassford J, Soeiro I, Skarell SM, et al. BCR targets cyclin D2 via Btk and the p85alpha subunit of PI3-K to induce cell cycle progression in primary mouse B cells. Oncogene. 2003;22:2248-2259.
5. Bajpai UD, Zhang K, Teutsch M, Sen R, Wortis HH. Bruton's tyrosine kinase links the B cell receptor to nuclear factor kappaB activation. J Exp Med. 2000;191:1735-1744.
6. Petro JB, Khan WN. Phospholipase C-gamma 2 couples Bruton's tyrosine kinase to the NF-kappaB signaling pathway in B lymphocytes. J Biol Chem. 2001;276:1715-1719.
7. Vassilev A, Ozer Z, Navara C, Mahajan S, Uckun FM. Bruton's tyrosine kinase as an inhibitor of the Fas/CD95 death-inducing signaling complex. J Biol Chem. 1999;274:1646-1656.
8. Verschuren MC, Kraakman ME, Mensink RG, Schuurman RK, van Dongen JJ, Hendriks RW. The Bruton's tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stages. Eur J Immunol. 1993;23:3109-3114.
9. Martínez N, Camacho FI, Ruíz-Ballesteros E, et al. Variability in the degree of expression of phosphorylated IkappaBalpha in chronic lymphocytic leukemia cases with nodal involvement. Clin Cancer Res. 2004;10:6796-6806.
10. Ortolano S, Hwang IY, Han SB, Kehrl JH. Roles for phosphoinositide 3-kinases, Bruton's tyrosine kinase, and Jun kinases in B lymphocyte chemotaxis and homing. Eur J Immunol. 2006;36:1285-1295.
11. Uckun F, Dibirdik I, Sarkissian A, Qazi S. In vitro and in vivo chemosensitizing activity of LFM-A13, a dual-function inhibitor of Bruton's tyrosine kinase and polo-like kinases, against human leukemic B-cell precursors. Arzneimittelforschung. 2011;61:252-259.
12. American Cancer Society. What are the key statistics for chronic lymphocytic leukemia? 2013. Available from: http://www.cancer.org/cancer/leukemia-chroniclymphocyticcll/detailedguide/leukemia-chronic-lymphocytic-key-statistics. Accessed February 5, 2013.
13. Gaynon PS. Childhood acute lymphoblastic leukaemia and relapse. Br J Haematol. 2005;131:579-587.
14. Gaynon PS, Trigg M, Uckun FM. Childhood acute lymphoblastic leukemia. In: Holland J, Frei E, Bast R, editors. Cancer Medicine. 5th ed. Hamilton (ON): BC Decker; 2000.
15. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354:166-178.
16. Leukemia and Lymphoma Society. Leukemia facts and statistics. 2012. Available from: http://www.lls.org/#/diseaseinformation/getinforma tionsupport/factsstatistics/leukemia. Accessed February 5, 2013.
17. Abbott BL. Chronic lymphocytic leukemia: recent advances in diagnosis and treatment. Oncologist. 2006;11:21-30.
18. Byrd JC, Lin TS, Grever MR. Treatment of relapsed chronic lymphocytic leukemia: old and new therapies. Semin Oncol. 2006;33:210-219.
19. Wierda WG, O'Brien SM. Initial therapy for patients with chronic lymphocytic leukemia. Semin Oncol. 2006;33:202-209.
20. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005;352:804-815.
21. Pleyer L, Egle A, Hartmann TN, Greil R. Molecular and cellular mechanisms of CLL: novel therapeutic approaches. Nat Rev Clin Oncol. 2009;6:405-418.
22. Zenz T, Mertens D, Kuppers R, Dohner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer. 2010;10:37-50.
23. Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood. 2009;114:3367-3375.
24. Smit LA, Hallaert DY, Spijker R, et al. Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity. Blood. 2007;109:1660-1668.
25. Herishanu Y, Perez-Galan P, Liu D, et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood. 2011;117:563-574.
26. Stevenson FK, Krysov S, Davies AJ, Steele AJ, Packham G. B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 2011;118:4313-4320.
27. Lin K, Glenn MA, Harris RJ, et al. c-Abl expression in chronic lymphocytic leukemia cells: clinical and therapeutic implications. Cancer Res. 2006;66:7801-7809.
28. Trigg ME, Gaynon P, Uckun FM. Cancer Medicine. 4th ed. Holland JF, Bast RC Jr, Morton DL, Fry E 3rd, Kufe DW, Weichselbaum RL, editors. Baltimore: Williams and Wilkins; 1996.
29. Moricke A, Zimmermann M, Reiter A, et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia. 2010;24:265-284.
30. Salzer WL, Devidas M, Carroll WL, et al. Long-term results of the Pediatric Oncology Group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the Children's Oncology Group. Leukemia. 2010;24:355-370.
31. Gaynon PS, Harris RE, Altman AJ, et al. Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children's Oncology Group Study CCG-1941. J Clin Oncol. 2006;24:3150-3156.
32. Eapen M, Raetz E, Zhang MJ, et al. Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in second remission: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research. Blood. 2006;107:4961-4967.
33. Roy A, Cargill A, Love S, et al. Outcome after first relapse in childhood acute lymphoblastic leukemia-lessons from the United Kingdom R2 trial. Br J Hematol. 2005;130:67-75.
34. Uckun FM, Morar S, Qazi S. Vinorelbine-based salvage chemotherapy for therapy-refractory aggressive leukemias. Br J Haematol. 2006;135:500-508.
35. Malempati S, Gaynon PS, Sather H, La MK, Stork LC; Children's Oncology Group. Outcome after relapse among children with standard-risk acute lymphoblastic leukemia: Children's Oncology Group study CCG-1952. J Clin Oncol. 2007;25:5800-5807.
36. Uckun FM, Jaszcz W, Chandan-Langlie M, Waddick KG, Gajl-Peczalska K, Song CW. Intrinsic radiation resistance of primary clonogenic blasts from children with newly diagnosed B-cell precursor acute lymphoblastic leukemia. J Clin Invest. 1993;91:1044-1051.
37. Uckun F M, Song CW. Lack of CD24 antigen expression in B-lineage acute lymphoblastic leukemia is associated with intrinsic radiation resistance of primary clonogenic blasts. Blood. 1993;81:1323-1332.
38. Uckun FM, Chandan-Langlie M, Jaszcz W, Obuz V, Waddick K, Song CW. Radiation damage repair capacity of primary clonogenic blasts in acute lymphoblastic leukemia. Cancer Res. 1993;53:1431-1436.
39. Larson RA. The US trials in adult acute lymphoblastic leukemia. Ann Hematol. 2004;83 Suppl 1:S127-S128.
40. Annino L, Vegna ML, Camera A, et al. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood. 2002;99:863-871.
41. Goekbuget N, Arnold R, Buechner T, Ganser A. Intensification of induction and consolidation improves only subgroups of adult ALL: analysis of 1200 patients in GMALL study 05/93. Blood. 2001;98:802a.
42. Thomas X, Boiron JM, Huguet F, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol. 2004;22:4075-4086.
43. Nachman JB, Sather HN, Sensel MG, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med. 1998;338:1663-1671.
44. Uckun FM. Treating chronic leukemias. Minnesota Physician. 2002;16:14.
45. Evrard S, Gaussem P, Helley D, Darnige L. Prognostic factors in chronic lymphocytic leukaemia: contribution of recent biological markers. Ann Biol Clin (Paris). 2005;63:589-597. French.
46. Korte W, Cogliatti S. Chronic lymphocytic leukemia-the old and the new. Ther Umsch. 2004;61:151-156. German.
47. Pangalis GA, Vassilakopoulos TP, Dimopoulou MN, Siakantaris MP, Kontopidou FN, Angelopoulou MK. B-chronic lymphocytic leukemia: practical aspects. Hematol Oncol. 2002;20:103-146.
48. Faria de Jr, de Oliveira JS, Delbone de Faria RM, et al. Prognosis related to staging systems for chronic lymphocytic leukemia. Sao Paulo Med J. 2000;118:83-88.
49. Moreno C, Villamor N, Colomer D, et al. Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. J Clin Oncol. 2005;23:3433-3438.
50. Kaku H, Horikawa K, Obata Y, et al. NF-kappaB is required for CD38-mediated induction of C(gamma)1germline transcripts inmurine B lymphocytes. Int Immunol. 2002;14:1055-1064.
51. Uckun FM, Waddick KG, Mahajan S, et al. BTK as a mediator of radiation-induced apoptosis in DT-40 lymphoma B cells. Science. 1996;273:1096-1100.
52. Takatsu K. Role of interleukin-5in immune regulation and inflammation. Nippon Rinsho. 2004;62:1941-1951. Japanese.
53. Ruiz-Ballesteros E, Mollejo M, Rodriguez A, et al. Splenic marginal zone lymphoma: proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis. Blood. 2006;106:1831-1838.
54. Tibes R, Trent J, Kurzrock R. Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics. Annu Rev Pharmacol Toxicol. 2005;45:357-384.
55. Chalandon Y, Schwaller J. Targeting mutated protein tyrosine kinases and their signaling pathways in hematologic malignancies. Haematologica. 2005;90:949-968.
56. Krause DS, Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med. 2005;353:172-187.
57. Stiller CA. International patterns of cancer incidence in adolescents. Cancer Treat Rev. 2007;33:631-645.
58. Gross TG, Termuhlen AM. Pediatric non-Hodgkin's lymphoma. Curr Oncol Rep. 2007;9:459-465.
59. Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med. 2010;362:1417-1429.
60. Monti S, Savage KJ, Kutok JL, et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood. 2005;105:1851-1861.
61. Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463:88-92.
62. Davies AJ, Rosenwald A, Wright G, et al. Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms. Br J Haematol. 2007;136:286-293.
63. Montoto S, Fitzgibbon J. Transformation of indolent B-cell lymphomas. J Clin Oncol. 2011;29:1827-1834.
64. Weniger MA, Wiestner A. Molecular targeted approaches in mantle cell lymphoma. Semin Hematol. 2011;3:214-226.
65. Herman SE, Gordon AL, Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011;23:6287-6296.
66. Minter AR, Simpson H, Weiss BM, Landgren O. Bone disease from monoclonal gammopathy of undetermined significance to multiple myeloma: pathogenesis, interventions, and future opportunities. Semin Hematol. 2011;1:55-65.
67. Raje N, Roodman GD. Advances in the biology and treatment of bone disease in multiple myeloma. Clin Cancer Res. 2011;6:1278-1286.
68. Abe M, Hiura K, Ozaki S, Kido S, Matsumoto T. Vicious cycle between myeloma cell binding to bone marrow stromal cells via VLA-4-VCAM-1 adhesion and macrophage inflammatory protein-1alpha and MIP-1beta production. J Bone Miner Metab. 2009;1:16-23.
69. Zannettino AC, Farrugia AN, Kortesidis A, et al. Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Cancer Res. 2005;5:1700-1709.
70. Takeuchi K, Abe M, Hiasa M, et al. TGF-beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth. PLoS One. 2010;3:e9870.
71. Vallet S, Mukherjee S, Vaghela N, et al. Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proc Natl Acad Sci U S A. 2010;11:5124-5129.
72. Moreaux J, Veyrune JL, De Vos J, Klein B. APRIL is overexpressed in cancer: link with tumor progression. BMC Cancer. 2009;9:83.
73. Tai YT, Li XF, Breitkreutz I, et al. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 2006;13:6675-6682.
74. Kline M, Donovan K, Wellik L, et al. Cytokine and chemokine profiles in multiple myeloma; significance of stromal interaction and correlation of IL-8 production with disease progression. Leuk Res. 2007;5:591-598.
75. Lee SH, Kim T, Jeong D, Kim N, Choi Y. The tec family tyrosine kinase Btk regulates RANKL-induced osteoclast maturation. J Biol Chem. 2008;17:11526-11534.
76. Tai YT, Chang BY, Kong SY, et al. Bruton's tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood. 2012;120:1877-1887.
77. Eifert C. An RNAi Screen Targeting the Protein Tyrosine Kinases Identifies Bruton's Tyrosine Kinase (BTK) as a Breast Cancer Cell Survival Factor [dissertation]. Albany: State University of New York; 2009.
78. Conklin DS, Eifert C, Kourtidis A. Bruton's tyrosine kinase as anti-cancer drug target. US patent application 20120165395. June 28, 2012.
79. Lavitrano M, Grassilli E, Helin K. Isoform of bruton's tyrosine kinase (BTK) protein. US patent 8,232,085. July 31, 2012.
80. Uckun FM, Zheng Y, Ghosh S. BTK inhibitors and methods for their identification and use. US patent 6,160,010. December 12, 2000.
81. Uckun FM, Zheng Y, Ghosh S. BTK inhibitors and methods for their identification and use. US patent 6,221,900. April 24, 2001.
82. Uckun FM, Zheng Y, Ghosh S. BTK inhibitors and methods for their identification and use. US patent 6,294,575. September 25, 2001.
83. Uckun FM, Zheng Y, Ghosh S. BTK inhibitors and methods for their identification and use. US patent 6,303,652. October 16, 2001.
84. Uckun FM, Zheng Y, Ghosh S. BTK inhibitors and methods for their identification and use. US patent 6,365,626. April 2, 2002.
85. Uckun FM, Malaviya R. BTK inhibitors and methods for their identification and use. US patent 6,753,348. June 22, 2004.
86. Uckun FM, Zheng Y, Ghosh S. BTK Inhibitors and methods for their identification and use European patent 1 071 658 B1. June 16, 2004.
87. Zhu Z. Intrabodies. US patent application 20100143371. June 10, 2010.
88. Honigberg L. Inhibitors of Bruton's tyrosine kinase. US patent application 20100041677. February 18, 2010.
89. Honigberg L, Verner E, Pan Z. Inhibitors of Bruton's tyrosine kinase. US patent application 20100022561. January 28, 2010.
90. Honigberg L, Verner E, Pan Z. Inhibitors of Bruton's tyrosine kinase. US patent application 20100004270. January 7, 2010.
91. Honigberg L, Verner E, Pan Z. Inhibitors of Bruton's tyrosine kinase. US patent application 20080139582. June 12, 2008.
92. Tripp M, Babish J, Bland J, et al. Substituted 1,3-cyclopentadione multi-target protein kinase modulators of cancer, angiogenesis and the inflammatory pathways associated therewith. US patent application 20100137449. June 10, 2010.
93. Kennedy-Smith J, Kondru RK, Loe BE, et al. Inhibitors of Bruton's tyrosine kinase. US patent application 20100099659. April 22, 2010.
94. Jankowski OD, Palmer JT, Honigberg L. Inhibitors of tyrosine kinases and uses thereof. US patent application 20100035841. February 11, 2010.
95. Johns RA, Su Q, Champion HC. HIMF and BTK in pulmonary, cardiac, and inflammation disorders. US patent application 20100028355. February 4, 2010.
96. Dewdney NJ, Lou Y, Sjogren E, Soth M, Sweeney ZK. Inhibitors of Bruton's tyrosine kinase. US patent application 20100004231. January 7, 2010.
97. Dewdney NJ, Kondru RK, Loe BE, et al. Inhibitors of Bruton's tyrosine kinase. US patent application 20090318448. December 24, 2009.
98. Dewdney NJ, Kennedy-Smith J, Kondru RK, et al. Inhibitors of Bruton's tyrosine kinase. US patent application 20090306041. December 10, 2009.
99. Dewdney NJ, Lou Y, Sjogren E, Soth M. Inhibitors of Bruton's tyrosine kinase. US patent application 20100016301. January 21, 2010.
100. Pan Z, Scheerens H, Li SJ, et al. Discovery of selective irreversible inhibitors of Bruton's tyrosine kinase. Chem Med Chem. 2007;2:58-61.
101. Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 2010;107:13075-13080.
102. Singh J, Petter RC, Kluge AF. Targeted covalent drugs of the kinase family. Curr Opin Chem Biol. 2010;14:1-6.
103. Evans E, Tester R, Aslanian S, et al. A novel platform-based approach to silence oncoproteins using small molecule therapeutics-application to Bruton's tyrosine kinase. Paper presented at the 100th AACR Annual Meeting; April 18-22, 2009; Denver, CO, USA.
104. Marcotte DJ, Liu YT, Arduini RM, et al. Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases. Protein Sci. 2010;19:429-439.
105. Hantschel O, Rix U, Schmidt U, et al. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci U S A. 2007;104:13283-13288.
106. Mao C, Zhou M, Uckun FM. Crystal structure of Bruton's tyrosine kinase domain suggests a novel pathway for activation and provides insights into the molecular basis of X-linked agammaglobulinemia. J Biol Chem. 2001;276:41435-41443.
107. Herman SE, Gordon AL, Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011;23:6287-6296.
108. Ponader S, Chen SS, Buggy JJ, et al. Bruton's tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012;119:1182-1189.
109. de Rooij MF, Kuil A, Geest CR, et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor-and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood. 2012;119:2590-2594.
110. Chang BY, Huang MM, Francesco M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res Ther. 2011;4:R115.
111. Holler C, Pinon JD, Denk U, et al. PKCbeta is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKCbeta as a therapeutic target in chronic lymphocytic leukemia. Blood. 2009;113:2791-2794.
112. Gorgun G, Ramsay AG, Holderried TA, et al. E(μ)-TCL1mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. Proc Natl Acad Sci U S A. 2009;106:6250-6255.
113. Johnson AJ, Lucas DM, Muthusamy N, et al. Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia. Blood. 2006;108:1334-1338.
114. Burger JA, O'Brien S, Fowler N, et al. The Bruton's tyrosine kinase inhibitor, PCI-32765, is well tolerated and demonstrates promising clinical activity in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): an update on ongoing phase 1 studies. Blood. 2010;116:32a.
115. Advani R, Sharman JP, Smith SM, et al. Effect of Btk inhibitor PCI-32765 monotherapy on responses in patients with relapsed aggressive NHL: evidence of antitumor activity from a phase I study [abstract]. J Clin Oncol. 2010;28:15s.
116. Advani R, Sharman J, Smith ST, et al. The Btk inhibitor PCI-32765 is highly active and well tolerated in patients with relapsed/refractory B cell malignancies: final results from a phase I study. Ann Oncol. 2011;22 Suppl 4:iv135-iv137.
117. Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor Ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31:88-94.
118. Fowler N, Sharman JP, Smith SM, et al. The Btk inhibitor, PCI-32765, induces durable responses with minimal toxicity in patients with relapsed/refractory B-cell malignancies: results from a phase I study. ASH Annual Meeting Abstracts. Blood. 2010;116:964A.
119. Fowler NH, Advani RH, Sharman JP, et al. The Bruton's tyrosine kinase inhibitor ibrutinib (PCl-32765) is active and tolerated in relapsed follicular lymphoma. Paper presented at the 2012ASH Annual Meeting; December 8-11, 2012; Atlanta, GA, USA. Abstract 156.
120. Staudt LM, Dunleavy K, Buggy JJ, et al. The Bruton's tyrosine kinase (Btk) inhibitor PCI-32765modulates chronic active BCR signaling and induces tumor regression in relapsed/refractory ABC DLBCL. Blood (ASH Annual Meeting Abstract) 2011;118:abstract 2716.
121. Harrison C. Trial watch: BTK inhibitor shows positive results in B cell malignancies. Nat Rev Drug Discov. 2012;11:96.
122. Wang M, Rule SA, Martin P, et al. Interim results of an international, multicenter, phase 2study of Bruton's tyrosine kinase (BTK) inhibitor, Ibrutinib (PCI-32765), in relapsed or refractory mantle cell lymphoma (MCL): durable efficacy and tolerability with longer follow-up. 2012 ASH Annual Meeting, December 8-11, 2012; Atlanta, GA, USA. Abstract 904.
123. Ponader P, Balasubramanian S, Pham LV, et al. Activity of Bruton's tyrosine kinase (BTK) inhibitor PCI-32765in mantle cell lymphoma (MCL) identified BTK as a novel therapeutic target. 53rd ASH Annual Meeting, December 10-13, 2011, San Diego, CA, USA. Abstract 3688.
124. Wilson WH, Gerecitano JF, Goy A, et al. The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, has preferential activity in the ABC subtype of relapsed/refractory de novo diffuse large B-cell lymphoma (DLBCL): interim results of a multicenter, open-label, phase 2study. 2012ASH Annual Meeting, December 8-11, 2012; Atlanta, GA, USA. Abstract 686.
125. O'Brien S, Burger JA, Blum KA, et al. The Bruton's Tyrosine Kinase Inhibitor PCI-32765 Induces Durable Responses in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Follow-up of a Phase Ib/II Study. 53rd ASH Annual Meeting, December 10-13, 2011, San Diego, CA, USA. Abstract 983.
126. O'Brien S, Burger JA, Coutre SE, et al. The Btk Inhibitor PCI-32765 is highly active and tolerable in patients with poor-risk CLL: interim results from a phase Ib/II study. Ann Oncol. 2011;22 Suppl 4: iv123-iv124.
127. O'Brien S, Burger JA. Blum KA, et al. The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765induces durable responses in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): follow-up of a phase Ib/II study. Blood. 2011;118:449.
128. O'Brien S, Furman RF, Coutre SE, et al. The Bruton's tyrosine kinase inhibitor ibrutinib (PCI-32765) is highly active and tolerable in relapsed or refractory and treatment naive chronic lymphocytic leukemia patients, updated results of a phase Ib/II study. 17th Congress of European Hematology Association, June 14-17, 2012; Amsterdam, The Netherlands, 2012Abstract 1970.
129. Byrd JC, Furman RR, Coutre SE, et al. The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 (P) in treatment-naive (TN) chronic lymphocytic leukemia (CLL) patients (pts): interim results of a phase Ib/II study. J Clin Oncol. 2012;Suppl 30:6507.
130. Byrd JC. Furman RR, Coutre S, Flinn IW, Burger JA, Blum KA. The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib promotes high response rate, durable remissions, and is tolerable in treatment naïve (TN) and relapsed or refractory (RR) CLL or SLL patients including patients with high-risk (HR) disease: new and updated results of 116 patients in a phase Ib/II Study. 2012ASH Annual Meeting, December 8-11, 2012; Atlanta, GA, USA. Abstract 189.
131. Burger JA, Keating MJ, Wierda WG, et al. The Btk inhibitor ibrutinib (PCI-32765) in combination with rituximab is well tolerated and displays profound activity in high-risk chronic lymphocytic leukemia (CLL) patients. 2012ASH Annual Meeting, December 8-11, 2012; Atlanta, GA, USA. Abstract 187.
132. Brown JR, Barrientos J, Flinn IW, et al. Combination of the Bruton's tyrosine kinase inhibitor PCI-32765 with bendamustine/rituximab (BR) in patients with relapsed/refractory chronic lymphocytic leukemia: interim results of a phase Ib/II study. 17th Congress of European Hematology Association, Amsterdam, The Netherlands, June 14-17 2012. Abstract 1590.
133. O'Brien SM, Barrientos JC, Flinn IW, et al. Combination of the Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 with bendamustine (B)/rituximab (R) (BR) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): interim results of a phase Ib/II study. J Clin Oncol. 2012;Suppl 30:6515.
134. Jaglowski SM, Jones JA, Flynn JM, et al. A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases. J Clin Oncol. 2012;Suppl 30:6508.
135. Advani R, Sharman JP, Smith SM, et al. Effect of BTK inhibitor PCI-32765 monotherapy on responses in patients with relapsed aggressive NHL: evidence of anti-tumor activity from a phase I study. J Clin Oncol. 2010;Suppl 28:8012.
136. Singh J, Russell P, Deqiang N, et al. Protein kinase conjugates and inhibitors. US patent application 20110117073. May 19, 2011.
137. Evans E, Tester R, Aslanian S, et al. A novel platform-based approach to silence oncoproteins using small molecule therapeutics-application to Bruton's tyrosine kinase. Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; April 18-22, 2009, Denver, CO, USA. Abstract 3739.
138. Evans E, Sheets M, Bernar H, et al. Prolonged inhibition of BCR signaling and suppression of B cell lymphoma through irreversible inhibition of Bruton's tyrosine kinase [abstract]. Blood. 2008;112:904.
139. Evans E, Ponader S, Karp R, et al. Covalent inhibition of Btk with clinical development compound AVL-292 disrupts signaling that maintains the microenvironment necessary for chronic lymphocytic leukemia growth [abstract]. Clin Lymphoma Myeloma Leuk. 2011;11 Suppl 2:S173-S174.
140. Eda H, Santo L, Cirstea DD, et al. Targeting Bruton's tyrosine kinase as a novel approach to inhibit osteoclast function in multiple myeloma [abstract]. Blood. 2011;118:1243.
141. Evans E, Tester R, Sharon A, et al. Translational medicine of a selective inhibitor of Btk in rheumatic diseases: pharmacology and early clinical development [abstract]. Arthritis Rheum. 2011;63 Suppl 10:1757.
142. Evans E, Teste R, Aslanian S, et al. Clinical development of AVL-292; a potent, selective covalent Btk inhibitor for the treatment of B cell malignancies [abstract]. Blood. 2011;118:1487.
143. Westlin WF, Stiede K, Lounsbury H, et al. Translational medicine enables rapid early clinical development of AVL-292, a highly selective, orally available inhibitor of Bruton's tyrosine kinase, in a phase 1b clinical trial. Cancer Res. 2012;72 Suppl 8:1745.
144. Hantschel O, Rix U, Superti-Furga G. Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk Lymphoma. 2008;49:615-619.
145. Hallaert DY, Jaspers A, van Noesel CJ, van Oers MH, Kater AP, Eldering E. Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches. Blood. 2008;112:5141-5149.
146. Eldering E, Geest CR, de Rooij MFM, et al. Mapping the targets of dasatinib in chronic lymphocytic leukemia reveals distinct roles for Abl and Btk in drug resistance and adhesion, and explains clinical effects on lymph node reduction. Proceedings: 2012ASH Annual Meeting, December 8-11, 2012, Atlanta, GA, USA. Abstract 3900.
147. Amrein PC, Attar EC, Takvorian T, et al. Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res. 2011;17:2977-2986.
148. Mahajan S, Ghosh S, Sudbeck EA, et al. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl) propenamide]. J Biol Chem. 1999;274:9587-9599.
149. Ghosh S, Jennissen JD, Zheng Y, Uckun FM. Three leflunomide metabolite analogs. Acta Crystallogr C. 2000;56:1254-1257.
150. Kim YJ, Sekiya F, Poulin B, Bae YS, Rhee SG. Mechanism of B-cell receptor-induced phosphorylation and activation of phospholipase C-gamma2. Mol Cell Biol. 2004;24:9986-9999.
151. Heinonen JE, Smith CI, Nore BF. Silencing of Bruton's tyrosine kinase (Btk) using short interfering RNA duplexes (siRNA). FEBS Lett. 2002;527:274-278.
152. Uckun FM, Ozer Z, Qazi S, Tuel-Ahlgren L, Mao C. Polo-like-kinase 1 (PLK1) as a molecular target to overcome SYK-mediated resistance of B-lineage acute lymphoblastic leukaemia cells to oxidative stress. Br J Haematol. 2010;148:714-725.
153. Uckun FM, Dibirdik I, Qazi S, et al. Anti-breast cancer activity of LFM-A13, a potent inhibitor of polo-like kinase (PLK). Bioorg Med Chem. 2007;15:800-814.
154. Uckun FM. Chemosensitizing anti-cancer activity of LFM-A13, a leflunomide metabolite analog targeting polo-like kinases. Cell Cycle. 2007;6:3021-3026.
155. Uckun FM. Rationally designed anti-mitotic agents with pro-apoptotic activity. Curr Pharm Des. 2001;7:1627-39.
156. Uckun FM, Zheng Y, Cetkovic-Cvrlje M, et al. In vivo pharmacokinetic features, toxicity profile, and chemosensitizing activity of alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl) propenamide (LFM-A13), a novel antileukemic agent targeting Bruton's tyrosine kinase. Clin Cancer Res. 2002;8:1224-1233.
157. Cetkovic-Cvrlje M, Uckun FM. Dual targeting of Bruton's tyrosine kinase and Janus kinase 3 with rationally designed inhibitors prevents graft-versus-host disease (GVHD) in a murine allogeneic bone marrow transplantation model. Br J Hematol. 2004;126:821-827.
158. Kozaki R, Yoshizawa T, Yasuhiro T, et al. Development of a Bruton's tyrosine kinase (Btk) inhibitor-ONO-WG-307, a potential treatment for B-cell malignancies. Cancer Res. 2012;72 Suppl B:857.
159. Yasuhiro T, Yoshizawa T, Daub H, Weber C, Narita M, Kawabata K. ONO-WG-307, a novel, potent and selective inhibitor of Bruton's tyrosine kinase (Btk), results in sustained inhibition of the ERK, AKT and PKD signaling pathways. Cancer Res. 2012;72 Suppl B:2021.
160. Liu L, Di Paolo J, Barbosa J, Rong H, Reif K, Wong H. Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy. J Pharmacol Exp Ther. 2011;338:154-163.
161. Liu L, Halladay JS, Shin Y, et al. Significant species difference in amide hydrolysis of GDC-0834, a novel potent and selective Bruton's tyrosine kinase inhibitor. Drug Metab Dispos. 2011;39:1840-1849.